{"title":"Anakinra有望治疗类风湿关节炎患者。","authors":"T. McIntosh, T. Freeman","doi":"10.1331/108658002763029661","DOIUrl":null,"url":null,"abstract":"Rheumatoid arthritis (RA) is a disease characterized by chronic, progressive destruction of cartilage and bone at multiple joints and inflammation of other body organs. It affects an estimated 2 million Americans, or less than 1.0% of the U.S. population. 1 The disease can be seen in people of all ages, but peak onset is between the ages of 20 and 45. It is at least two times more common in women than in men. 1 .","PeriodicalId":17212,"journal":{"name":"Journal of the American Pharmaceutical Association","volume":"PP 1","pages":"660-2"},"PeriodicalIF":0.0000,"publicationDate":"2002-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":"{\"title\":\"Anakinra shows promise for treating patients with rheumatoid arthritis.\",\"authors\":\"T. McIntosh, T. Freeman\",\"doi\":\"10.1331/108658002763029661\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rheumatoid arthritis (RA) is a disease characterized by chronic, progressive destruction of cartilage and bone at multiple joints and inflammation of other body organs. It affects an estimated 2 million Americans, or less than 1.0% of the U.S. population. 1 The disease can be seen in people of all ages, but peak onset is between the ages of 20 and 45. It is at least two times more common in women than in men. 1 .\",\"PeriodicalId\":17212,\"journal\":{\"name\":\"Journal of the American Pharmaceutical Association\",\"volume\":\"PP 1\",\"pages\":\"660-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2002-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Pharmaceutical Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1331/108658002763029661\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Pharmaceutical Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1331/108658002763029661","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Anakinra shows promise for treating patients with rheumatoid arthritis.
Rheumatoid arthritis (RA) is a disease characterized by chronic, progressive destruction of cartilage and bone at multiple joints and inflammation of other body organs. It affects an estimated 2 million Americans, or less than 1.0% of the U.S. population. 1 The disease can be seen in people of all ages, but peak onset is between the ages of 20 and 45. It is at least two times more common in women than in men. 1 .
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
